Background: Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary end point but reported notable survival benefit with tecemotide versus placebo in an exploratory analysis of the predefined patient subgroup treated with concurrent chemoradiotherapy. Here, we attempted to gain further insight into the effects of tecemotide in START.
introduction Therapeutic gains in the management of unresectable stage III non-small-cell lung cancer (NSCLC) have been modest. The standard of care, concurrent chemoradiotherapy, yields a 5-year survival rate of ∼15% [1] and phase III studies examining consolidation therapy following chemoradiotherapy have been disappointing [2] . There is growing interest in lung cancer immunotherapy.
Stimulating Targeted Antigenic Responses To NSCLC (START) was a phase III trial of the MUC1-antigen-specific cancer immunotherapy, tecemotide, following chemoradiotherapy for unresectable stage III NSCLC (n = 1239) [3] . Despite not meeting the primary end point of survival prolongation, there was a survival benefit with tecemotide in the predefined subgroup treated with concurrent chemoradiotherapy (n = 806; HR 0.78, 95% CI 0.64-0.95, P = 0.016). Secondary end points, time to symptom progression (TTSP), and time to progression (TTP), supported a benefit in this subgroup.
Biomarker data may provide additional insights. MUC1, a large glycoprotein present on the apical membranes of normal secretory epithelial cells, is aberrantly glycosylated and overexpressed in many cancers including NSCLC [4] . Reported levels of MUC1 overexpression in NSCLC range from ∼40% to ∼95% [5] [6] [7] . Soluble MUC1 (sMUC1), the extracellular N-terminal subunit of cellular MUC1, is shed into the circulation by MUC1-positive tumors and normal epithelial cells [8, 9] . sMUC1 was therefore measured as a potential indicator of tumor burden. Antinuclear antibodies (ANA) were examined because they have been demonstrated in patients with several types of cancer, including lung cancer [10] , and are associated with improved survival in NSCLC [11] . High neutrophil/ lymphocyte ratio (NLR) and high lymphocyte count were assessed because they are independent negative and positive prognostic factors, respectively, in NSCLC [12] [13] [14] . Three prespecified HLA types were also tested following a phase IIb study [15] and suggested a degree of HLA dependency with tecemotide (data on file).
patients and methods

patient populations
The START study is described in detail elsewhere [3] . Briefly, START assessed tecemotide in unresectable, stage III NSCLC following two or more cycles of platinum-based chemotherapy and radiotherapy (≥50 Gy). Patients with responding or stable disease within 4-12 weeks following chemoradiotherapy were randomized to receive tecemotide or placebo. Updated OS was assessed in the modified ITT (mITT) population and biomarker analyses were conducted for patients in this population for whom baseline results were available.
The study was performed in compliance with the principles of the International Conference on Harmonisation Guidelines on Good Clinical Practice and Declaration of Helsinki, and approved according to local regulatory requirements and by each center's research ethics board. All patients gave written informed consent.
study design and treatment
Subcutaneous tecemotide (806 μg lipopeptide) or placebo was administered as previously described [3] . Tecemotide comprised the MUC1-derived 25-amino acid BLP25 lipopeptide, the immunoadjuvant monophosphoryl lipid A, and three liposome-forming lipids. Placebo comprised the liposomeforming lipids only. Imaging intervals were determined by institutional standards.
study end points
We present updated OS data and prespecified, exploratory biomarker OS analyses, including sMUC1, ANA, lymphocyte count, NLR, and HLA. Blood for biomarker analysis was collected following completion of chemoradiation and prior to study therapy.
We defined the upper limit of normal (ULN) for sMUC1 and NLR as 25 IU/ml and 5, respectively. The ANA cut-off was 1:160 and the lower limit of normal (LLN) for lymphocytes was 1.02 × 10 9 /l. Additional methodology is provided in supplementary Appendix, available at Annals of Oncology online.
statistical considerations
The primary analysis population was the mITT population of 1239 patients, prospectively defined to exclude patients randomized within 6 months prior to a clinical hold (described in detail previously [3] ). OS was analyzed by the Kaplan-Meier method and Cox proportional hazards regression models adjusting for randomization strata. All reported P values are two-sided and not adjusted for multiplicity. Biomarker analyses are exploratory.
results baseline characteristics
Patient disposition is presented in supplementary Figure S1 , available at Annals of Oncology online. The study arms in the mITT and biomarker populations were evenly matched for important baseline characteristics. No notable characteristics were linked to baseline biomarker levels ( Table 1, supplementary  Table S1 , available at Annals of Oncology online).
updated overall survival
The updated overall survival (OS) data include 20 months' additional observation beyond the primary analysis, increasing the median follow-up time to 58.7 months (tecemotide) and 57. Figure 1A ). In the concurrent chemoradiotherapy subgroup, median survival was 29.4 months with tecemotide versus 20.8 months with placebo (OS aHR 0.81, 95% CI 0.68-0.98, P = 0.026; Figure 1B ). OS was similar in both arms in the sequential chemoradiotherapy subgroup (median 20.7 versus 25.5 months, respectively; aHR 1.04, 95% CI 0.82-1.31, P = 0.761; Figure 1C ).
exploratory biomarker analyses
The prognostic and predictive associations for each biomarker are summarized in Table 2 .
sMUC1 levels. In the tecemotide-treated group, 276 (37%) patients had high sMUC1 and 465 (63%) low sMUC1. In the placebo group, 123 (35%) had high sMUC1 and 233 (65%) low sMUC1. A negative prognostic association with OS was observed for high versus low sMUC1 levels with placebo (n = 356, aHR 1.53, 95% CI 1.18-1.99, P = 0.0013). Prolonged OS with tecemotide versus placebo was seen in the high sMUC1 group (n = 399, aHR 0.66, 95% CI 0.51-0.85, P = 0.0010), but not the low sMUC1 group (n = 698, aHR 1.00, 95% CI 0.83-1.22, P = 0.97; Figure 2A ) (interaction P = 0.0085). In the concurrent chemoradiotherapy subgroup, high versus low sMUC1 levels correlated with a greater treatment effect with tecemotide ( Figure 2B) ; this was not evident with sequential chemoradiotherapy ( Figure 2C ) (interaction P-values 0.0066 and 0.538, respectively).
Analysis by sMUC1 quartiles did not reveal a consistent trend of increased treatment effect with increasing sMUC1 levels. The greatest treatment effect was seen in the highest sMUC1 quartile groups in the mITT population (29.1 < sMUC1 IU/ml; aHR 0.61, 95% CI 0.46-0.82, P = 0.0009), the concurrent chemoradiotherapy subgroup (28.6 < sMUC1 IU/ml, aHR 0.55, 95% CI 0.38-0.80, P = 0.0019), and the sequential chemoradiotherapy subgroup (30.2 < sMUC1 IU/ml, aHR 0.60, 95% CI 0.36-1.01, P = 0.0525) (Figure 3 ). It should be noted, however, that the highest sMUC1 quartiles are a subset of the high sMUC1 group defined by the ULN. No correlation between sMUC1 and other biomarkers was observed (supplementary Table S2 , available at Annals of Oncology online).
ANA titers. High ANA titers (≥1:160) were observed in only 82 (10%) patients receiving tecemotide and 46 (12%) patients receiving placebo. High versus low ANA titer was associated with poorer OS with placebo (n = 397, aHR 1.43, 95% CI 1.01-2.03, P = 0.0422).
OS was prolonged with tecemotide versus placebo in the high ANA subgroup (n = 128; aHR 0.43, 95% CI 0.26-0.69, P = 0.0005), but not the low ANA subgroup (n = 1065; aHR 0.96, 95% CI 0.82-1.12, P = 0.6233; Figure 2A ) (interaction P-value 0.0022). High ANA titers also indicated a greater treatment effect with tecemotide in the concurrent (interaction P-value 0.0016) but not sequential (interaction P-value 0.6671) chemoradiotherapy subgroups ( Figure 2B and C) . lymphocyte count. Lymphopenia was observed in 507 patients (66%) receiving tecemotide and 265 patients (69%) receiving placebo. Lymphocyte count had no prognostic association with OS in the placebo group (aHR 1.00, 95% CI 0.77-1.30, P = 0.9957).
A trend toward improved survival with tecemotide versus placebo was observed with lymphocyte count ≥LLN (n = 385, aHR 0.81, 95% CI 0.62-1.06, P = 0.1282, Figure 2A ), but not at lower lymphocyte counts (n = 772, aHR 0.94, 95% CI 0.79-1.13, P = 0.5066). No interaction was observed between lymphocyte count and tecemotide treatment effect in the mITT population (P = 0.3127) or the concurrent or sequential chemoradiotherapy subgroups. neutrophil:lymphocyte ratio. A high NLR was observed in 377 (49%) patients receiving tecemotide and 201 (52%) patients receiving placebo. In the latter, high versus low NLR was associated with poorer OS (aHR 1.37, 95% CI 1.07-1.75, P = 0.0132).
A trend toward improved survival with tecemotide versus placebo with elevated (n = 578, HR 0.81, 95% CI 0.66-0.99, P = 0.0383, Figure 2A ), but not low (n = 579, HR 1.02, 95% CI 0.82-1.27, P = 0.8785), NLR was observed. However, the interaction was not significant in the mITT population (interaction P-value 0.1454), or with concurrent chemoradiotherapy. In the sequential chemoradiotherapy subgroup, there was apparent interaction between NLR and treatment effect favoring the NLR >5 subset (interaction P-value 0.0343). Table S3 , available at Annals of Oncology online).
There was a trend toward treatment benefit with tecemotide with HLA-DRB4 positivity; however, the interaction was not significant (P = 0.25). Supplementary Table S4 , available at Annals of Oncology online, shows OS by HLA types occurring in >5% of patients.
discussion
These updated OS data are consistent with the primary analysis [3] . Of note, the OS curve separation is maintained over prolonged follow-up. The initial trend towards an unfavorable effect in the sequential chemoradiotherapy subgroup (HR 1.12) plateaued over time (HR 1.04). In parallel, the observed OS effect in the concurrent chemoradiotherapy subgroup was reduced, but remains clinically relevant (median OS difference: 8.6 months; aHR 0.81, 95% CI 0.68-0.98, P = 0.0263).
The biomarker analyses presented here are exploratory. Importantly, baseline samples were taken before commencing tecemotide treatment, but after completion of initial chemoradiotherapy. The potential effect of chemoradiotherapy on the tested markers is unknown. Furthermore, the study population was limited to patients who did not progress after initial chemoradiotherapy. Since multiple analyses were performed, the prognostic and predictive associations of biomarkers might lessen or even disappear with adjustment for multiplicity, which was not formally conducted. Thus, these factors demand caution when interpreting possible prognostic and predictive associations.
We observed a negative prognostic association between high sMUC1 and OS in the placebo arm. Poor outcomes with high sMUC1 levels have been reported previously in two small NSCLC studies [16, 17] and may reflect greater disease burden in MUC1-expressing cancers [8, 17, 18] . In a study of 103 patients, Tanaka et al. reported that MUC1 was present in all NSCLC tissues analyzed following curative resection, and sMUC1 fell dramatically following surgery [17] . Suppression of T-cell-mediated immunity may also contribute to a negative prognostic effect of high sMUC1. Tumor-associated sMUC1 has been shown to inhibit T-cell proliferation, cytokine secretion, and cytotoxic activity [19, 20] .
The potential positive predictive value of high sMUC1 for tecemotide therapy is interesting in light of the apparent negative prognostic associations, and the proposed mechanism of action of tecemotide via induction of a T-cell response against MUC1-expressing tumor cells [21] . High sMUC1 levels may reflect increased MUC1 expression by tumor cells, providing a target for tecemotide-induced cellular immunity. This hypothesis could not be tested here as tumor biopsies were not collected and the influence of prior chemoradiotherapy on baseline sMUC1 levels is unknown. Studies indicating a positive relationship between tumor burden and sMUC1 levels [8, 17, 18] support the theory that tumor tissue is the primary origin of circulating sMUC1, although a recent small study has suggested otherwise [22] .
In START, high ANA titers correlated negatively with survival in the absence of tecemotide, contrasting with a previous small study showing ANA to be an independent prognostic factor for better survival [11] . The importance of the predictive value of high ANA titers therefore remains unclear. Previous studies indicate that high ANA titers may reflect a preactivated immune system, facilitating a survival benefit from tecemotide-induced immunity. Our data do not support this conclusion, possibly reflecting limitations of the biomarker analysis or patient population differences between START and previous studies.
The potential positive predictive value of high sMUC1 levels and high ANA titers was observed in the mITT population and the concurrent, but not sequential, chemoradiotherapy subgroup. There was no obvious imbalance in sMUC1 levels between chemoradiotherapy subgroups that could explain this, and no satisfactory explanation for the lack of observed benefit from tecemotide among sequentially treated patients. Approximately 50% of patients in each arm had high NLR, largely reflecting lymphopenia because neutrophilia was rare. High NLR was a negative prognostic indicator but did not have predictive associations.
As the BLP25 lipopeptide appears to be presented by APCs in the context of MHC/HLA, it is plausible that certain HLA alleles may present the lipopeptide more effectively than others. However, no association between prespecified HLA types and outcomes was observed.
Our analyses have inherent strengths and limitations. Standardized cut-off values were chosen for the biomarkers, offering a degree of generalizability. However, the biomarker analyses are exploratory, and potential effects must be interpreted with caution. In addition to the limitations described earlier, subpopulations were relatively small.
The START updated OS data are generally consistent with the primary analysis, but with an overall reduced difference between the sequential and concurrent pretreatment subgroups. However, a lack of observed benefit with tecemotide in study EMR 63325-009, including in patients receiving concurrent chemoradiotherapy, was recently announced. EMR 63325-009 was a randomized, placebo-controlled, double-blind, phase I/II clinical trial in Japanese patients (n = 172) with stage III, unresectable, locally advanced NSCLC. The data indicated no effect for the primary (OS) and secondary end points ( progression-free survival, time to treatment failure, and time to progression). Differences in outcome between START and this underpowered study may be due to smaller patient numbers, or possibly genetic differences between Japanese and Caucasian patients, where potential differences in HLA Class I and II alleles may have an unknown effect on the efficacy of immunotherapy. Nevertheless, based on these results, Merck Serono announced in September 2014 that the clinical development of tecemotide in stage III NSCLC will be discontinued.
Overall, the START results support a potentially greater treatment effect of tecemotide in Caucasian patients treated with concurrent chemoradiotherapy, with OS benefits maintained on long-term follow-up. The findings reported here suggest potential prognostic and predictive roles for sMUC1 and ANA.
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